IP Library › Granted Patent US 10,479,793
Granted Patent B2
US 10,479,793 · App. 15/776,094 · Granted Nov 19, 2019

Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

Inventors: David S. Weinstein (San Diego, CA); Ryan M. Moslin (Princeton, NJ); Yanlei Zhang (Princeton, NJ); Daniel S. Gardner (Furlong, PA); Joseph B. Santella (Springfield, PA); Charles M. Langevine (Brooklyn, NY); Sylwia Stachura (Flemington, NJ)
Assignee: Bristol-Myers Squibb Company
C07D487/04A61K31/5025A61K31/53A61K31/5377A61P29/00A61P37/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,479,793
App. No.
15/776,094
Granted
Nov 19, 2019
Kind
B2
Abstract

Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Claims (21)

1. A compound of the formula

wherein

R 1 is —NHR 2 ;

R 2 is C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl;

R 3 is H, C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl or mono or bicyclic C 3 -C 8 cycloalkyl;

R 4 is H, C 1 -C 6 alkyl, mono or bicyclic C 3 -C 6 cycloalkyl, phenyl, or pyridyl, any of said groups other than H substituted with 0-4 R 7 ;

R 5 is H or C 1 -C 4 alkyl;

R 7 is H, halo, CN, CF 3 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CONH C 1 -C 6 alkyl, —CONH halo C 1 -C 6 alkyl, —CONH halo C 1 -C 6 alkoxy, heteroaryl, or aryl, said aryl and heteroaryl groups substituted with 0-2 R 8 ;

R 8 is H, halo, CF 3 , C 1 -C 4 alkyl or C 1 -C 4 alkoxy;

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

2. The compound according to claim 1

wherein

R 1 is —NHR 2 ;

R 2 is CH 3 or cyclopropyl;

R 3 is H, C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl or mono or bicyclic C 3 -C 8 cycloalkyl;

R 4 is H, C 1 -C 6 alkyl, mono or bicyclic C 3 -C 6 cycloalkyl, phenyl, or pyridyl, any of said groups other than H substituted with 0-4 R 7 ;

R 5 is H or C 1 -C 4 alkyl;

R 7 is H, halo, CN, CF 3 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CONH C 1 -C 6 alkyl, —CONH halo C 1 -C 6 alkyl, —CONH halo C 1 -C 6 alkoxy, heteroaryl, or aryl, said aryl and heteroaryl groups substituted with 0-2 R 8 ;

R 8 is H, halo, CF 3 , C 1 -C 4 alkyl or C 1 -C 4 alkoxy;

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

3. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent.

Continuity (3)
Provisional Application 62404827 · Oct 6, 2016
Provisional Application 62256784 · Nov 18, 2015
Related Publication 20180325899A1 · Nov 15, 2018